Allergy & Immunology
COVID-vaccine results are on the way — and scientists’ concerns are growing
28 Sep, 2020 | 01:33h | UTCCOVID-vaccine results are on the way — and scientists’ concerns are growing – Nature
Commentary on Twitter
Several ongoing coronavirus-vaccine trials could announce game-changing results next month. Scientists, though, have growing concerns. Here are the three areas they are watching closely. https://t.co/QxyA1zM0rY
— Nature Portfolio (@NaturePortfolio) September 26, 2020
Britain will ‘host world’s first Covid-19 vaccine challenge trial’
24 Sep, 2020 | 09:22h | UTC
How close is a coronavirus vaccine?
24 Sep, 2020 | 09:25h | UTCHow close is a coronavirus vaccine? – Financial Times
Commentary on Twitter
A very good infographic on the #SARSCoV2 vaccineshttps://t.co/iIXQPUEecN @FT via @NChildersMEP
1. What is a Phase 3 trial? Number of events, efficacy pic.twitter.com/tbwtdOOYoB— Eric Topol (@EricTopol) September 24, 2020
What COVID-19 reinfection means for vaccines
24 Sep, 2020 | 09:23h | UTCWhat COVID-19 Reinfection Means for Vaccines – Scientific American
Long-term COVID-19 containment will be shaped by strength, duration of immunity
23 Sep, 2020 | 14:51h | UTCOriginal Article: Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years – Science
NICE Guideline: Antimicrobial prescribing for insect bites and stings
23 Sep, 2020 | 14:40h | UTC
What can we expect from first-generation COVID-19 vaccines?
22 Sep, 2020 | 10:02h | UTCWhat can we expect from first-generation COVID-19 vaccines? – The Lancet
Commentary on Twitter
We need to calibrate our expectations for the 1st generation of #SARSCoV2 vaccines https://t.co/QTJbyOd9xQ @TheLancet by @gmleunghku and Malik Peiris @hkumed Pe-covid normalcy is not near. pic.twitter.com/Y15TqfoRlf
— Eric Topol (@EricTopol) September 21, 2020
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
Covid-19: Do many people have pre-existing immunity?
18 Sep, 2020 | 09:41h | UTCCovid-19: Do many people have pre-existing immunity? – The BMJ
Commentary on Twitter
It seemed a truth universally acknowledged that the human population had no pre-existing immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging research on immunological responseshttps://t.co/6LYRjxlWBQ
— The BMJ (@bmj_latest) September 17, 2020
Change in antibodies to SARS-CoV-2 over 60 days among health care personnel
18 Sep, 2020 | 09:32h | UTC
Commentary on Twitter
In this cohort study, anti–SARS-CoV-2 antibodies decreased over 60d in HCWs w 58% becoming seronegative. The results suggest that x-sectional seroprevalence studies may underestimate rates of prior infections because Abs may only be transiently detectable https://t.co/IHgURuDJYm
— JAMA (@JAMA_current) September 18, 2020
[Press release – not published yet] Eli Lilly reports first, promising results for an antibody against COVID-19
17 Sep, 2020 | 09:28h | UTCEli Lilly reports first, promising results for an antibody against COVID-19 – Science
Press release: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine
The lasting misery of coronavirus long-haulers
15 Sep, 2020 | 09:05h | UTCThe lasting misery of coronavirus long-haulers – Nature
Viewpoint: COVID-19 and the path to immunity
14 Sep, 2020 | 01:20h | UTCCOVID-19 and the Path to Immunity – JAMA
Commentary on Twitter
Declines in SARSCoV2 IgG neutralizing Abs raise concerns of susceptibility to reinfection. But acute Ab levels always decline post-infection, and Ab recall responses come from a pool of long-lived memory B cells https://t.co/geGOQkhdw2
— JAMA (@JAMA_current) September 12, 2020
COVID-19 herd immunity: Where are we?
14 Sep, 2020 | 01:18h | UTCCOVID-19 herd immunity: where are we? – Nature Reviews Immunology
Commentary on Twitter
This is one of the most succinct and best written short pieces on herd immunity, what it is and where we are heading with #COVID19.
If not comfortable with math, just get through the first sentences and it’s worth continuing the read. https://t.co/1F3MuQWkfc
— Michael Mina (@michaelmina_lab) September 13, 2020
The underdog coronavirus vaccines that the world will need if front runners stumble
11 Sep, 2020 | 01:20h | UTCThe underdog coronavirus vaccines that the world will need if front runners stumble – Nature
Opinion: Halting the Oxford vaccine trial doesn’t mean it’s not safe – it shows they’re following the right process
10 Sep, 2020 | 09:42h | UTC
A leading coronavirus vaccine trial is on hold: Scientists react
10 Sep, 2020 | 09:43h | UTCA leading coronavirus vaccine trial is on hold: scientists react – Nature
‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency
10 Sep, 2020 | 09:40h | UTC
Commentary on Twitter
Opinion: "In the middle of a pandemic — when the whole world, literally, is hoping a useful vaccine is on the horizon — everyone was left to guess what went wrong and what it might mean," @Pharmalot writes. https://t.co/jOpMyxC1dQ
— STAT (@statnews) September 9, 2020
AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.
9 Sep, 2020 | 09:45h | UTC
Commentary on Twitter
BREAKING: AstraZeneca's #Covid19 vaccine trials have been paused as the company investigates a serious adverse event the occurred in the UK. Not clear if the unexplained illness is linked to the vaccine, or what it was. https://t.co/wGqvvXIBTD
— Helen Branswell 🇨🇦 (@HelenBranswell) September 8, 2020
[Preprint] Randomized trial: Convalescent plasma not associated with improved outcomes in Covid-19
9 Sep, 2020 | 09:41h | UTC
Commentary on Twitter
Convalescent Plasma Randomized Controlled Trial (PLACID Trial) in the Management of Moderate #COVID19 (pre-print)
👉 “not associated with reduction in mortality or progression to severe COVID-19”
Link: https://t.co/2ZXnfemsas@GermHunterMD @MackayIM @CT_Bergstrom #IDTwitter pic.twitter.com/yZuOxVhbjL
— Alvin (@alvie_barr) September 8, 2020
The coronavirus is mutating — does it matter?
9 Sep, 2020 | 09:35h | UTCThe coronavirus is mutating — does it matter? – Nature
The immunology of multisystem inflammatory syndrome in children with COVID-19
9 Sep, 2020 | 09:33h | UTCThe Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 – Cell
Perspective: “When will WE have a vaccine?” — understanding questions and answers about Covid-19 vaccination
9 Sep, 2020 | 09:37h | UTC
Commentary on Twitter
People inquiring about Covid-19 vaccines often want to know when the public can be confident that available vaccines are safe and effective, when a vaccine will be available to people like them, and when uptake will be high enough to enable a return to prepandemic life. #COVID19
— NEJM (@NEJM) September 8, 2020
WHO: Emergency use approval is a “temporary solution,” countries should wait for large clinical trials to finish to roll out a COVID-19 vaccine en masse
8 Sep, 2020 | 01:21h | UTC